| __timestamp | Regeneron Pharmaceuticals, Inc. | Viking Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 1271353000 | 22223073 |
| Thursday, January 1, 2015 | 1620577000 | 6966842 |
| Friday, January 1, 2016 | 2052295000 | 9000499 |
| Sunday, January 1, 2017 | 2075142000 | 13741186 |
| Monday, January 1, 2018 | 2186100000 | 19040000 |
| Tuesday, January 1, 2019 | 3036600000 | 23559000 |
| Wednesday, January 1, 2020 | 2735000000 | 31931000 |
| Friday, January 1, 2021 | 2908100000 | 44981000 |
| Saturday, January 1, 2022 | 3592500000 | 54234000 |
| Sunday, January 1, 2023 | 4439000000 | 63806000 |
| Monday, January 1, 2024 | 5132000000 |
Unleashing the power of data
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Regeneron Pharmaceuticals, Inc. and Viking Therapeutics, Inc. have demonstrated contrasting approaches to R&D investment. Regeneron, a giant in the industry, has consistently increased its R&D expenses, culminating in a staggering 250% growth from 2014 to 2023. In 2023 alone, Regeneron allocated over 4.4 billion dollars to R&D, underscoring its dedication to pioneering new treatments.
In contrast, Viking Therapeutics, a smaller player, has shown a more modest yet steady increase in R&D spending, growing by nearly 190% over the same period. While Viking's R&D budget is a fraction of Regeneron's, its strategic investments reflect a focused approach to niche therapeutic areas. This financial commitment highlights the diverse strategies within the biotech sector, where both giants and emerging companies strive to lead in innovation.
Novartis AG or Viking Therapeutics, Inc.: Who Invests More in Innovation?
Comparing Innovation Spending: Bristol-Myers Squibb Company and Viking Therapeutics, Inc.
Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation
R&D Spending Showdown: Regeneron Pharmaceuticals, Inc. vs Bio-Techne Corporation
Research and Development Investment: Regeneron Pharmaceuticals, Inc. vs Pharming Group N.V.
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Ultragenyx Pharmaceutical Inc.
Analyzing R&D Budgets: Regeneron Pharmaceuticals, Inc. vs Veracyte, Inc.
Regeneron Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and MannKind Corporation
Who Prioritizes Innovation? R&D Spending Compared for Regeneron Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Research and Development: Comparing Key Metrics for Ascendis Pharma A/S and Viking Therapeutics, Inc.
R&D Insights: How Corcept Therapeutics Incorporated and Viking Therapeutics, Inc. Allocate Funds